153 results about "Enterotoxin" patented technology

Disclosed are immunopotentiating agents, and vaccines thereof, which enhance and/or otherwise modify immune responses, and method for their preparation and use in vivo. Immunopotentiating agents can be single agents that act directly, adjuvants added concurrently with the agents, or heteroconjugates wherein the immunopotentiating agent is chemically coupled to the compound against which an immune response is desired. Examples of immunopotentiating agents include monoclonal antibodies, such as anti-CD3, anti-CD2) and anti-CD5 antibodies, and proteins derived from microorganisms (e.g., enterotoxins) which activate T cells. The compounds against which an immune response can be generated, which may be the second component in a heteroconjugate, include compound from abnormal or diseased tissues such as tumors, or infectious agents, such as viruses, bacteria, fungi, protozoal or metozoal parasites, and can be obtained by natural or recombinant means. Methods of using the invention to prepare monoclonal antibodies are particularly disclosed.

The invention discloses high levels of receptors for Clostridium perfringens enterotoxin (CPE) have been found in ovarian cancer and uterine cancer tissue samples. In addition, successful in vivo treatment of a mouse model of ovarian cancer with intraperitoneal injection of CPE is disclosed. High levels of Ep-CAM protein is also disclosed in ovarian cancer tissue samples. Thus, the invention provides a method of treating ovarian cancer and uterine cancer by administering CPE. The invention also provides a method of treating cancer in a mammal involving intraperitoneal administration of CPE, where at least some cancerous cells are located in or adjacent to the peritoneal cavity of the mammal. The invention also provides a method of treating ovarian cancer involving administering an anti-Ep-CAM antibody. The invention also provides a method of treating cancers expressing claudin-3 or claudin-4 by administering an antibody against claudin-3 and/or an antibody against claudin-4. The invention also provides a method of protecting a mammal from CPE toxicity involving administering a protective agent that binds to claudin-3 and/or claudin-4 and inhibits CPE binding to claudin-3 and/or claudin-4.

The present invention discloses an isolated pure culture of a novel strain CK1 of Bacillus licheniformis, BCRC 910458, capable of detoxification of zearalenone (ZEN). Using physiological, biochemical, morphological identification and 16S rRNA gene sequence analysis methods, the strain CK1 was identified as Bacillus licheniformis. Through extracellular xylanase, CMCase protease assays and evaluations for zearalenone detoxification, the strain CK1 strain was identified to possess good ZEN-detoxifying ability, to be non-hemolytic, non-enterotoxin producing, and displayed high levels of extracellular xylanase, cellulase, and protease activities. Accordingly, Bacillus licheniformis CK1 can be applied as food and feed supplement for bio-detoxification of ZEN.

The invention discloses recombinant engineering bacteria for efficiently expressing human growth hormone (hGH), a construction method and an application and provides an escherichia coli operon for expressing recombinant hGH, an expression plasmid containing an operon sequence and engineering bacteria QJSW-SZ01 (CGMCC No:7258) used for secretory expression of the recombinant hGH and obtained by transformation of the expression plasmid containing the operon. The recombinant engineering bacteria are characterized in that a coding sequence of a signal peptide of an escherichia coli heat-stable enterotoxin is changed, and rare codons of escherichia coli in the coding sequence are mutated so as to avoid formation of a secondary structure; meanwhile, an amino acid is altered on the terminal of the coding sequence so that the coding sequence is more beneficial to guidance of secretory expression of hGH; the signal peptide, an escherichia coli alkaline phosphatsae promoter (phoA promoter) and an escherichia coli T7 terminator are combined to be used as an expression control element so that the recombinant hGH is efficiently secretory-expressed in the escherichia coli in a soluble form. The recombinant engineering bacteria lay the foundation of finally developing a low-cost hGH pharmaceutical product.

The invention discloses a recombination Staphylococcus aureus enteritis toxin E with SEQ ID NO.1 amino acid sequence, which is composed of pGEX-4T-1 and SEQ ID NO.2 nucleotide sequence. The invention utilizes hyperantigen activity to accelerate the breeding of splenocyte and inhibit tumour from growing, which is fit for preparing high-purity enterotoxin and hyperantigen agent.

An immunogenic detoxified protein is provided which comprises the amino acid sequence of subunit A of an E. coli heat labile toxin (LT-A) or a fragment thereof in which at least amino acid Ala-72 of the A subunit is mutated, preferably by substitution with Arg. The toxoid is useful as vaccine against an enterotoxigenic strain of E. coli and is produced by recombinant DNA means by site-directed mutagenesis. It is also an effective adjuvant.

An orally applied filtrate of staphylococcus aureus for improving immunity and increasing the number of white cells and white platelets in human body contains enterotoxin SEA, SEB, SEC, SED and TSST-1. Its advantages are sure curative effect and low toxic by-effect.

The invention relates to a manufacture method and application of an immune sensor based on a polyaniline nano-particle composite membrane. By manufacturing the polyaniline nano-particle composite membrane, self-conductivity of materials is improved, and the membrane can be successfully applied to the immune sensor so as to greatly reduce detection limits of the sensor and achieve better stability. Representation and measurement of the sensor are performed through a cyclic voltammetry method and an alternate current impedance method, a staphylococcus aureus enterotoxin B detection standard curve is built, the linear range ranges from 0.1ng/ml to 8ng/ml, correlation coefficient R2=0.9932, and detection limit is 0.033ng/ml(S/N=3). The manufacture method and the application are good in specificity, can be used repeatedly, are good in stability, can be applied to fast detection of staphylococcus aureus enterotoxin B in dairy products and has wide application prospect, and dairy product detection recovery rate ranges from 84% to 111%.

The invention discloses methicillin-resistant staphylococcus aureus (MRSA) recombinant multivalent subunit genetic engineering vaccine and a method for preparing the same. The recombinant multivalent subunit genetic engineering vaccine is prepared by recombining, fussing and expressing the active and functional fragments of two antigen molecules of ClfA and IsdB and the specific enterotoxin C mutant for the MRSA to construct recombinant multivalent genetic engineering antigen protein under the assistance of aluminum adjuvant. The recombinant multivalent subunit genetic engineering vaccine is constructed with a unique method and prepared with simple process, is easy to be amplified and has good repeatability and high protein purity. The experiment on the animal shows that the recombinant multivalent subunit genetic engineering vaccine can effectively stimulate the body to produce higher humoral immune response and have good immune protection function.

Provided herein are reagents, compositions, and therapies with which to treat Clostridium difficile infection and related disease conditions and pathologies, such as Clostridium difficile-associated diarrhea, resulting from infection by Clostridium difficile bacteria and the enterotoxins produced by these bacteria. In particular, antibodies or antigen-binding fragments thereof that bind specifically to toxin A and/or toxin B of C difficile and neutralize the activities of these toxins; compositions comprising such antibodies; and methods of using the antibodies and the compositions are provided.

A recombinant Methicillin-resistant Staphylococcus aureus enterotoxin N belongs to a super antigen with SEQ ID NO.1 amino acid sequence, which is expressed by a recombination of a gene coding SEN from the Staphylococcus aureus and a plasmid vector, and a transformation to the proper host and is obtained a recombinant a highly purified SEN protein by affinity purification. The invention proves the recombinant protein has a typical super antigen activity better than SEC and can be applied in the preparation of activating the lymphocytes multiplication and inhibiting the tumor cell proliferation. The product is suitable for preparing the highly purified enterotoxin with the super antigen activity and exploiting super antigen agent. The invention has a wise design, purifies the target protein with affinity chromatography, has a simple process and a high purification speed.

The invention discloses a gene recombinant vaccine for preventing enterovirus 71 (EV71) infection and a preparation method thereof. The inflection comprises multiple diseases related with the nervous system such as hand-foot-and-mouth disease, paralytic diseases of sterile meningitis, cephalitis and poliomyelitis and the like. Escherichia coli labile enterotoxin B subunit (LTB) is used as an immunological enhancement adjuvant, two fragments of linear neutralizing epitope SP55 and SP70 in EV71 virus coat protein VP1 are used as antigens, prokaryotic expression plasmids of LTB-SP55-SP70 fusion genes are constructed by using gene engineering technology, the plasmids are expressed in escherichia coli, and a recombinant expression product is purified for preparing the EV71 virus gene engineering vaccine.

The invention relates to a multi-PCR (polymerase chain reaction)-based method for quickly detecting four diarrhoeic Escherichia coli and special primers thereof. The method comprises the following steps: respectively selecting enterohemorrhagic Escherichia coli O157:H7O-antigen gene, enterotoxigenic Echerichia coli LT gene, enteropathogenic Echerichia coli bfpA gene and enteroinvasive Echerichia coli invasion plasmid gene as target genes, carrying out comparative analysis on the gene sequences, selecting the conserved region of the target gene sequence to design and synthesize the primers which are disclosed as SEQ ID NO.1-8 in the sequence table, and establishing a multi-PCR detection method to carry out qualitative detection on the four diarrhoeic Escherichia coli. The method provided by the invention has strong detection specificity. The invention also relates to a kit for detection. The invention is quick and simple and has the advantages of high accuracy and high sensitivity.

The present invention provides a kit and a method for simultaneously detecting Staphylococcus aureus and five enterotoxins thereof. The kit comprises a pair of universal primers, a fluorescent probe and a hybridization linking probe designed according to the specific genes of Staphylococcus aureus and five enterotoxins thereof. According to the detection method, the DNA of the suspected bacteria extracted from a sample to be detected is adopted as a template, detection is performed by combining a multiple linking probe amplification technology and a fluorescent probe melting curve technology, and the conditions of the Staphylococcus aureus and the five enterotoxins thereof in the sample to be detected are analyzed and treated through the melting curve.

A set of oligonucleotide probe for detecting the enterohemorrhagic E. coli O157:H7 and cholera vibrio O139 is designed on the Shiga-like toxin generating gene stx1 or stx2 and the beta-glucuronidase gene uidA of said enterohemorrhagic E coli O157:H7 and the enterotoxin A subset (ctxA), toxicity coordinate pilus A subset (tcpA) and glucosyltransferase (LPS gt) genes of cholera vibrio O139, and has high sensibility and specificity. It can be used to detect the enterohemorrhagic E. coli O157:H7, cholera vibrio O139 and other pathogenic genes from the specimen.

The invention relates to a veterinary Chinese medicinal composition for improving growth performance and enhancing the non-specific immune function of an organism. The composition is prepared from the following raw material medicaments: Chinese pulsatilla root, astragalus, large head atractylodes rhizome, indigowoad root, baical skullcap root, bupleurum and rhubarb. The invention also relates to a veterinary medicament prepared from the veterinary Chinese medicinal composition, a method for preparing the veterinary medicament and the application of the veterinary Chinese medicinal composition. The veterinary Chinese medicinal composition has the effects of strengthening body resistance, eliminating evil, clearing away heat and toxic material and enhancing the non-specific immune function of the organism and can treat various atypical symptoms such as low immune function of the organism, immune tolerance, endogenous toxin, stress and the like, the decrease of the growth performance and damp-heat symptoms such as anemopyretic cold, flu, gumboro disease, enterotoxin syndrome and the like.

The invention relates to a genetic engineering technology, in particular to a superantigen mutant protein gene of enterotoxin C2 and a method for cloning, expressing and preparing the same. The superantigen mutant protein gene of the enterotoxin C2 comprises base sequences in tables of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 and SEQ ID NO: 4. Allogenetic expression of the superantigen mutant protein gene provides development potential of the enterotoxin C2 in the anti-tumor aspect; and the superantigen mutant protein gene performs deletion mutant on an amino terminal thereof on the basis of SEC2, the amino terminal affects the biological activity, and mutant protein kept with the superantigen activity is expected to be obtained on the basis simultaneously. The superantigen mutant protein gene of the enterotoxin C2 applied to preparing a superantigen anti-tumor biological agent has the characteristics of high yield, stable production, convenient purification and the like.

The invention is based on the identification of aminopeptidase N (APN) as the receptor for F4 fimbriae of enterotoxigenic E. coli (ETEC). Based on the observation that oral administration of F4 fimbriae induces a protective intestinal mucosal immune response against a subsequent challenge with F4 ETEC, and the observation that the internalization of said F4 fimbriae is clathrin-mediated, the present invention provides the characterization of APN as a target useful in: in an in vitro assay to screen for molecules that are capable to mimic the clathrin-mediated F4 endocytosis; in an in vitro assay to screen for molecules that are capable to modulate the binding of F4 fimbriae with APN; in the development of a carrier for the delivery of antigens/therapeutics, i.e. immunomodulators to the intestinal submucosa or the intestinal mucosa-associated lymphoid tissue, wherein said carrier comprises an APN specific target molecule that mimics the clathrin-mediated F4 endocytosis. The use of the carriers thus identified or the treatments thus identified, in a method of inducing an antigen specific intestinal mucosal immune response, and/or in the treatment of bacterial diarrhea, is a further aspect of the present invention.